A key strategy missing from the ambitious Alzheimer’s disease plan signed into law by President Obama six years ago could send investigational drugs down a precarious pipeline, argue two physicians from the Perelman School of Medicine at the University of Pennsylvania and the University of Michigan in JAMA Internal Medicine. The National Alzheimer Project Act (NAPA) calls for new treatments to slow or prevent the disease by 2025, but as it stands now, there’s no strategy in place to determine whether the interventions being studied today have a so-called “meaningful” clinical benefit for patients.

Share This Page: